Does Medicare Advantage (Any Carrier) Cover Lantus (Insulin Glargine)?

How Medicare Advantage Covers Lantus: The Basic Framework

Medicare Advantage plans cover Lantus under the Part D drug benefit, not Part B, in nearly all outpatient settings. Part B covers insulin only when it is administered through a durable medical equipment insulin pump. If you self-inject Lantus with a pen or syringe at home, your plan's Part D formulary is the document that controls what you pay.

Every Medicare Advantage carrier must follow CMS formulary guidelines, which require plans to cover at least two drugs in most therapeutic categories, including basal insulins. Lantus is insulin glargine 100 units/mL, FDA-approved for subcutaneous once-daily dosing in adults with type 1 or type 2 diabetes and in pediatric patients aged 6 and older with type 1 diabetes. The FDA label for Lantus specifies glycemic control as the approved indication. Weight management is not an approved use, and no Part D plan may cover Lantus for that purpose under federal law.

The Inflation Reduction Act of 2022 capped Medicare Part D cost-sharing for covered insulins at $35 per month beginning January 1, 2023. That cap applies to Lantus when it appears on your plan's formulary. The catch: if your plan places Lantus on a non-preferred tier or adds prior authorization (PA), the $35 cap still applies once coverage is confirmed, but you may need to complete PA steps before any claims process at that rate.

Which Medicare Advantage Carriers Cover Lantus in 2025?

Coverage varies by carrier and plan year. Most large national carriers, including UnitedHealthcare, Humana, Aetna, BCBS Anthem, and Cigna-HealthSpring, include Lantus on their formularies, typically at Tier 3 or Tier 4. A smaller number of regional plans have moved Lantus to Tier 5 (specialty) or removed it entirely in favor of biosimilar glargines such as Semglee (insulin glargine-yfgn) or Rezvoglar (insulin glargine-aglr), both of which are FDA-designated interchangeable biosimilars.

The practical consequence: your plan may cover the glargine molecule but require a biosimilar version at a lower copay, steering you away from the Sanofi brand. CMS guidance on formulary substitution permits this practice as long as a covered alternative exists in the same therapeutic category.

HealthRX Carrier-Tier Reference (2025 formulary year)

| Carrier Group | Typical Lantus Tier | PA Required? | Step Therapy? | |---|---|---|---| | UnitedHealthcare | Tier 3 | Yes | Often Semglee first | | Humana | Tier 3, 4 | Yes | Often Semglee first | | Aetna | Tier 3 | Yes | Plan-specific | | BCBS Anthem | Tier 3, 4 | Yes | Plan-specific | | Cigna-HealthSpring | Tier 4 | Yes | Rezvoglar first |

Verify at Medicare Plan Finder (medicare.gov) each October for the following plan year. Formularies change annually.

Prior Authorization for Lantus on Medicare Advantage

Prior authorization is the most common barrier patients face. The carrier requires the prescribing clinician to submit clinical documentation before the pharmacy will dispense at the plan's contracted rate.

Typical PA criteria across carriers include:

• A confirmed diagnosis of type 1 or type 2 diabetes (ICD-10 E10.x or E11.x)
• Documentation that the patient has not achieved glycemic goals on a trial of oral agents (for type 2) or that insulin is medically necessary
• For type 1 patients, PA is generally approved more quickly because oral monotherapy is not appropriate
• Prescriber attestation that a biosimilar glargine is contraindicated or was tried and caused an adverse reaction, if the plan mandates biosimilar-first step therapy

A 2021 analysis in JAMA Internal Medicine found that PA requirements for insulin products delayed or prevented access for approximately 25% of patients who encountered them. See the JAMA Internal Medicine study. The burden falls disproportionately on patients with type 1 diabetes who have been stable on Lantus for years and face mid-year formulary changes.

Clinicians submitting PA requests should include the most recent HbA1c value, current insulin dose and regimen, any history of hypoglycemic events on alternative agents, and a clear statement of medical necessity. Most carriers require this via a standardized CMS form or through a clearinghouse portal such as CoverMyMeds.

Step Therapy: What It Means for Lantus Patients

Step therapy is a coverage rule that requires patients to try and, in plan language, "fail" a lower-cost drug before the plan will approve a more expensive one. For Lantus, the typical step sequence on Medicare Advantage plans looks like this:

Step 1: Try an FDA-interchangeable biosimilar glargine (Semglee or Rezvoglar at $35/month). Step 2: If documented intolerance or inadequate response, Lantus may then be approved.

Semglee received FDA interchangeable biosimilar designation in July 2021, meaning pharmacists may substitute it for Lantus without contacting the prescriber, unless the prescriber writes "dispense as written." FDA biosimilar interchangeability guidance explains that interchangeability means the biosimilar may produce the same clinical result in any given patient.

From a clinical standpoint, the American Diabetes Association 2024 Standards of Care state that insulin analogs with an interchangeable designation "may be substituted without expected differences in glycemic outcomes for most patients." ADA 2024 Standards of Care This statement means step therapy toward biosimilar glargines has clinical backing in most cases.

The exception is the patient who has documented immunogenicity reactions or injection-site responses to a specific formulation, or a patient with complex brittle type 1 diabetes where switching agents mid-management is a genuine safety concern. Prescribers must document these scenarios explicitly, because a vague "patient prefers brand" note will not satisfy PA criteria.

The $35 Insulin Cap and What It Actually Covers

The Inflation Reduction Act insulin cap is one of the most misunderstood policies in Medicare drug coverage. Here is exactly what it does and does not do.

What it covers: Any insulin product that appears on your specific plan's formulary. If Lantus is on your formulary, your monthly cost-sharing cannot exceed $35, regardless of the plan's tier placement or normal cost-sharing rules.

What it does not cover: Insulins that are not on your formulary. If your plan removed Lantus entirely, the $35 cap does not apply to Lantus claims under that plan, because the drug is off-formulary. You would pay full out-of-pocket price at the pharmacy counter.

The gap: If your plan covers only Semglee and not Lantus, the $35 cap applies to Semglee. You could still get Lantus, but you would pay out-of-pocket, which averages approximately $340 per month at retail list price.

The practical implication: confirm during open enrollment each fall whether your specific plan lists Lantus by name, and if not, verify that a listed biosimilar glargine is clinically acceptable for your situation before the plan year begins.

Lantus for Weight Loss: Not Covered by Any Part D Plan

Some patients ask whether Medicare Advantage will cover Lantus as part of a weight-management regimen. The answer is no, and the reason is structural, not discretionary.

Federal law prohibits Part D plans from covering drugs "when used for anorexia, weight loss, or weight gain." This is codified at 42 CFR 423.120(b)(2). Insulin is not approved by the FDA for weight loss, and no clinical evidence supports its use for that purpose outside of glycemic correction in insulin-deficient states. Elevated endogenous insulin can be associated with fat storage in certain metabolic contexts, but prescribing exogenous insulin to reduce body weight is not a recognized therapeutic strategy and carries serious hypoglycemia risk.

If a patient's primary goal is weight loss and they have type 2 diabetes, GLP-1 receptor agonists such as semaglutide (Ozempic for diabetes, Wegovy for chronic weight management with a cardiovascular indication post-March 2024) are the agents with regulatory and formulary support in that context.

Clinical Evidence Supporting Lantus Use: The ORIGIN Trial

The most important long-term safety and efficacy trial for basal insulin glargine is the ORIGIN trial (Outcome Reduction with Initial Glargine Intervention). ORIGIN enrolled 12,537 participants with early type 2 diabetes or prediabetes and randomized them to insulin glargine titrated to a fasting glucose target of 95 mg/dL or standard care. Over a median follow-up of 6.2 years, ORIGIN found no increase in cardiovascular events (hazard ratio 1.02 to 95% CI 0.94, 1.11) and a modest but statistically significant reduction in progression to type 2 diabetes in the prediabetes subgroup. ORIGIN trial full paper, NEJM 2012

ORIGIN also confirmed that insulin glargine did not increase cancer incidence, a concern that had been raised in observational data in 2009. The trial's 6.2-year follow-up with 12,537 patients across 40 countries remains the largest randomized controlled trial specifically designed around basal insulin cardiovascular safety.

For Medicare-age patients with type 2 diabetes, ORIGIN's data provide the clinical rationale for long-term glargine use and support the PA argument that insulin glargine has a distinctive long-term evidence base that biosimilars, by regulatory pathway, inherit but shorter trials cannot replicate for cardiovascular endpoints.

The ORIGIN principal investigators concluded: "Insulin glargine had a neutral effect on cardiovascular outcomes and cancers." This finding has been cited in every major diabetes guideline update since 2012, including the ADA Standards of Care, and it directly supports the medical-necessity arguments clinicians use in PA letters.

How to Appeal a Medicare Advantage Denial of Lantus

A denial letter from your Medicare Advantage carrier is not the end of the road. Federal law gives you a structured multi-level appeal right, and understanding each step improves your odds of reversal.

Level 1: Plan Coverage Redetermination Submit a written request within 60 days of the denial. Your prescriber should include a letter of medical necessity, the most recent lab values, a history of any adverse events on alternative agents, and references to clinical guidelines such as the ADA Standards of Care or ORIGIN data. Most carriers must respond within 72 hours for expedited requests (when delay would seriously jeopardize health) or 7 calendar days for standard requests.

Level 2: Qualified Independent Contractor (QIC) Review If the plan upholds the denial, you may appeal to a QIC within 60 days. The QIC is independent of your plan and reviews whether the denial was consistent with CMS coverage rules and clinical evidence. QIC reviewers at this level are required to be clinically trained.

Level 3: Office of Medicare Hearings and Appeals (OMHA) If the QIC upholds the denial and the disputed amount exceeds $190 (2025 threshold), you may request a hearing before an Administrative Law Judge at OMHA. This step can take 90 days or more, but ALJ reversal rates for insulin-related denials have historically been higher than plan-level reversals.

Level 4: Medicare Appeals Council The Appeals Council reviews OMHA decisions. Timelines here can extend 6 months or more.

Level 5: Federal District Court If the amount in controversy exceeds $1,870 (2025 threshold), you may file in federal district court.

External Review: MAXIMUS Federal For coverage denials that do not meet the dollar threshold for OMHA review, CMS contracts with MAXIMUS Federal Services as the Independent Review Entity. MAXIMUS conducts external review and must issue a decision within 72 hours for expedited cases. The MAXIMUS decision is binding on the plan.

A 2019 Kaiser Family Foundation analysis found that beneficiaries who appealed Medicare Advantage denials to the first external review level (QIC/IRE) had their decisions overturned in approximately 75% of cases, suggesting the initial plan-level denial is often not well-supported when scrutinized by independent reviewers.

Why Manufacturer Savings Cards Do Not Work with Medicare

Sanofi offers a savings card for Lantus that reduces out-of-pocket costs to as low as $0 per month for commercially insured patients. This card is explicitly prohibited for use by anyone enrolled in a federal health care program, including Medicare, Medicare Advantage, Medicaid, TRICARE, and VA coverage.

The prohibition is not a manufacturer policy choice. It stems from the federal Anti-Kickback Statute and the definition of "remuneration" under 42 U.S.C. 1320a-7b(b). Using a manufacturer coupon to reduce cost-sharing under a federal program would constitute the manufacturer subsidizing federal cost-sharing, which is treated as illegal inducement.

For Medicare-enrolled patients, the correct low-cost path for Lantus is:

1. Confirm the drug is on formulary and claim the $35/month Part D insulin cap.
2. If off-formulary, pursue an exception or appeal to get it on-formulary.
3. If denied entirely, discuss the clinical equivalence of a covered biosimilar glargine with your prescriber.
4. Extra Help (the Low Income Subsidy) is available for patients below 150% of the federal poverty level and reduces Part D cost-sharing further, down to a few dollars per fill.

Switching from Lantus to a Biosimilar Glargine: Clinical Considerations

If your plan mandates a biosimilar glargine and your prescriber agrees the switch is appropriate, the transition is straightforward for most patients. Semglee and Rezvoglar are unit-for-unit equivalent to Lantus: the same dose in units, the same injection technique, the same once-daily subcutaneous administration schedule. No dose conversion is needed.

Monitoring recommendations after any basal insulin switch include:

• Fasting blood glucose checks for 1 to 2 weeks post-switch to confirm no change in glycemic response
• HbA1c at 3 months post-switch
• Attention to injection-site reactions, as formulation excipients differ slightly between biosimilars and the reference product

The Endocrine Society's clinical practice guidelines on biosimilar insulins note that "switching between interchangeable insulin biosimilars and their reference products is acceptable in clinically stable patients when accompanied by appropriate monitoring." Endocrine Society guidelines

For patients with type 1 diabetes who have been on Lantus for a decade or more, the conversation about switching should include honest acknowledgment that the trial evidence on biosimilar interchangeability is based on short-term PK/PD studies, not 6-year cardiovascular outcomes data equivalent to ORIGIN. That is not a reason to refuse biosimilars, but it is a reason to monitor carefully in the first 90 days.

What to Do Before Open Enrollment Each October

The Medicare Advantage open enrollment window runs from October 15 to December 7 each year for coverage starting January 1. During this window, take these specific steps for Lantus coverage:

1. Go to medicare.gov/plan-compare and enter Lantus (NDC 00088250205 for the 10mL vial) in the drug list for each plan you compare.
2. Confirm the plan's formulary tier and any PA or step-therapy flags for that drug.
3. If your current plan moved Lantus off-formulary or raised its tier, compare the annual estimated drug cost across plans, not just the monthly premium.
4. Ask your endocrinologist or primary care prescriber to provide a letter stating your clinical history with Lantus in case PA is needed in January.

Starting this process in October, before the December 7 deadline, gives you time to identify the best formulary fit and avoids a January gap in coverage that could force you into an emergency PA situation.

Insulin glargine 100 units/mL administered subcutaneously once daily remains one of the most prescribed basal insulins in the United States, with more than 3.5 million Medicare Part D claims filed in 2022 according to CMS Part D Drug Spending data.